c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Xintong,Li ^[1] ; Ze,Zhang ^[2] ; Fangyan,Gao ^[1] ; Yuxuan,Ma ^[3] ; Dongying,Wei ^[2] ; Zhangwei,Lu ^[3] ; Siqi,Chen ^[2] ; Mengqi,Wang ^[4] ; Yueyao,Wang ^[2] ; Kun,Xu ^[1] ; Runtian,Wang ^[1] ; Feng,Xu ^[1] ; Jia-Yu,Chen ^[4] ; Chengjun,Zhu ^[1] ; Zhe,Li ^[3] ; Hanyang,Yu ^[2] ; Xiaoxiang,Guan ^[1]

作者单位： Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. ^[1] State Key Laboratory of Coordination Chemistry, Department of Biomedical Engineering, College of Engineering and Applied Sciences, Jiangsu Key Laboratory of Artificial Functional Materials, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing 210023, China. ^[2] State Key Laboratory of Analytical Chemistry for Life Science, Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing 210023, China. ^[3] State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing 210023, China. ^[4] Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing 210029, China. ^[5]